The acquisition also includes certain rights to share in future profits that may arise from a potential new medicine (MEDI8897).
The initial purchase price amounts to 1,500 MUSD and is made up by (i) new shares to be issued in Sobi in connection with closing and (ii) a MUSD 1,000 cash component that is financed by the bank syndicate. In addition to the initial purchase price certain contingent and conditional payments may become payable later on.
Swedish Orphan Biovitrum AB (publ) is an international biopharmaceutical company focused on rare diseases. It is an integrated company with specific capabilities in biologics within the areas of Haemophilia and Immunology.
Cederquist’s financing team included financing partner Johan Lundberg, senior associate Mirja Sikander and associate Marcus Hjorth.
For further information, please refer to the press release made public by Swedish Orphan Biovitrum AB (publ) as available at https://www.sobi.com/en/investors/sobitm-acquire-synagisr-us-rights-astrazeneca-creates-platform-global-growth.